Cost-effectiveness of rabies post-exposure prophylaxis in the context of very low rabies risk: A decision-tree model based on the experience of France

Vaccine
Florence Ribadeau DumasYazdan Yazdanpanah

Abstract

Benefit-risk of different anti-rabies post-exposure prophylaxis (PEP) strategies after scratches or bites from dogs with unknown rabies status is unknown in very low rabies risk settings. A cost-effectiveness analysis in metropolitan France using a decision-tree model and input data from 2001 to 2011. A cohort of 2807 patients, based on the mean annual number of patients exposed to category CII (minor scratches) or CIII (transdermal bite) dog attacks in metropolitan France between 2001 and 2011. Five PEP strategies: (A) no PEP for CII and CIII; (B) vaccine only for CIII; (C) vaccine for CII and CIII; (D) vaccine+ rabies immunoglobulin (RIG) only for CIII; and (E) vaccine for CII and vaccine+ RIG for CIII. The number of deaths related to rabies and to traffic accidents on the way to anti-rabies centers (ARC), effectiveness in terms of years of life gained by reducing rabies cases and avoiding traffic accidents, costs, and incremental cost-effectiveness ratios (ICER) associated with each strategy. Strategy E led to the fewest rabies cases (3.6 × 10(-8)) and the highest costs (€ 1,606,000) but also to 1.7 × 10(-3) lethal traffic accidents. Strategy A was associated with the most rabies cases (4.8 × 10(-6)), but the risk of traffic...Continue Reading

References

May 1, 1976·British Medical Journal·D A Robinson
Jan 1, 1988·Asia-Pacific Journal of Public Health·S ChutivongseH Wilde
Jan 1, 1985·Journal of Neurology·S JainM C Maheshwari
May 1, 1984·Anesthesiology·G B GillettR M Langford
Jul 1, 1995·American Journal of Public Health·S A Llorens, D Neuhauser
Jan 18, 2003·Vaccine·Y RotivelA Simons de Fanti
Jun 21, 2005·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·J PillonelS Laperche
May 20, 2008·Transactions of the Royal Society of Tropical Medicine and Hygiene·Henry WildeAlan C Jackson
Jul 5, 2008·Vaccine·Praveen DhankharMartin I Meltzer
Sep 2, 2008·Travel Medicine and Infectious Disease·Andreas GuntherChristian Schoenfeld
Feb 6, 2009·Emerging Infectious Diseases·Laurent DacheuxHervé Bourhy
Apr 30, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gaston De SerresBernard Duval
Sep 14, 2010·Vaccine·UNKNOWN WHO Publication
Aug 10, 2011·Zoonoses and Public Health·Z GongZ Chen
Dec 2, 2011·PLoS Neglected Tropical Diseases· TenzinMichael P Ward
Feb 22, 2012·Travel Medicine and Infectious Disease·M J Warrell
Apr 11, 2012·Risk Analysis : an Official Publication of the Society for Risk Analysis·A D GoddardE L Snary
Jan 29, 2013·Médecine sciences : M/S·Florence Ribadeau-DumasHervé Bourhy
Jun 14, 2013·Archives of Virology·Evelyne Picard-MeyerFlorence Cliquet
Jun 19, 2013·PLoS Medicine·Donald A Redelmeier, Barry A McLellan

❮ Previous
Next ❯

Citations

Jun 18, 2016·Emerging Infectious Diseases·Florence Ribadeau-DumasHervé Bourhy
Jan 30, 2020·Journal of Travel Medicine·Michael P MuehlenbeinUNKNOWN GeoSentinel Surveillance Network
Oct 4, 2018·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Perrine ParizeUNKNOWN The French Network Of Antirabies Clinics

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.